Introduction

!
Gastrointestinal tract cancer represents the leading cause of cancer death worldwide, with an estimated mortality over 1.75 million [1] . Early endoscopic detection and treatment of potentially curable cancers or precancerous lesions could potentially lead to a reduction of gastrointestinal cancer incidence and cancer related mortality [2 -5] . In the past decades, endoscopic resection therapies have gradually improved and gained more importance for premalignant lesions and noninvasive early cancers with a low risk of lymph node metastasis. The survival after endoscopic removal of an early cancer may be similar to that after surgical resection, providing the rationale for this approach [6, 7] . Resection-based modalities consist of endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). Injection-assisted EMR was first introduced in 1955 for rigid sigmoidoscopy [8] and then in 1973 for flexible colonoscopy [9] . In the following years, improvements in the EMR techniques, such as cap-assisted EMR and ligation method, have been introduced [10, 11] , and nowadays, EMR is a widely used and useful method to resect minimally invasive benign and early malignant lesions of the gastrointestinal tract [12] . However, despite its efficacy, this method is sometimes associated with local recurrence, especially when lesions larger than 40 mm are resected in a piecemeal fashion [13] . To overcome this limitation, ESD has been developed, allowing en bloc resection of superficial neoplasms and providing better histopathological diagnosis and decreased local recurrence rates [14 -16] . Endoscopic resection techniques are aided by mucosal elevation through the injection of a solution into the submucosal space. This technique may reduce complications, such as perforation or * These authors contributed equally to the study. Background and aims: Submucosal injection is standard practice in endoscopic mucosal resection of gastrointestinal lesions. Several solutions are used. Our aim was to systematically review their efficacy and safety. Patients and methods: We performed a systematic review and meta-analysis using a random effects model of randomized controlled trials (RCTs) from MEDLINE. Studies in animal models were qualitatively assessed for efficacy and safety. Results: In total, 54 studies were qualitatively assessed. Eleven RCTs were analyzed, two of which were on endoscopic submucosal dissection (ESD). The quantitative synthesis included nine RCTs on endoscopic mucosal resection (EMR), comprising 792 subjects and 793 lesions. Mean lesion size was 20.9 mm (range 8.5 -46 mm). A total of 209 lesions were randomized to sodium hyaluronate (SH) vs normal saline (NS), 72 to 50 % dextrose (D50) vs NS, 82 to D50 vs SH, 43 to succinylated gelatin, 25 to hydroxyethyl starch and 36 to fibrinogen. In total, 385 were randomized to NS as controls. NS and SH are the best studied solutions and seem to be equally effective in achieving complete resection (OR 1.09; 95 %CI 0.82, 1.45) . No solution was proven to be superior in complete resection rate, post-polypectomy bleeding or coagulation syndrome/perforation incidence. Many solutions have been tested in animal studies and most seem more effective for mucosal elevation than NS. Conclusions: There are several solutions in clinical use and many more under research, but most are poorly studied. SH seems to be clinically equivalent to NS. There are no significant differences in post-polypectomy complications. Larger RCTs are needed to determine any small differences that may exist between solutions.
bleeding and improve the technical feasibility of the procedure. The volume of injected fluid is highly variable and depends on the size and location of the lesion, and repeated injections may be needed for complete removal. Several solutions have been used to lift the mucosal lesion, but the optimal solution is still a matter of debate. It is accepted that the "ideal" solution for submucosal injection should provide a thick submucosal fluid cushion, remain in the submucosal space long enough to safely allow EMR or ESD, and preserve tissue specimens and allow for precise pathologic staging. In this setting, normal saline (NS) has been the most widely used solution as it is simple to use and available at a low cost. However, the mucosal protrusion created by the submucosal injection of normal saline solution is only maintained for a short period of time. This may not have a significant impact on the removal of small lesions but, when performing longer procedures or resecting larger lesions, the need for repeated injections in order to maintain the cushion may become problematic and the risk of perforation may be higher. In order to overcome these limitations and to improve the technical feasibility of EMR and ESD, several solutions have been studied. Submucosal injection of glucose solution, glycerol, sodium hyaluronate (SH), colloids, hydroxypropyl methylcellulose, fibrinogen solution, autologous blood, and other alternatives have been investigated in different contexts. Nevertheless, these solutions are also associated with some caveats: they can be difficult to prepare or administer, available at a high cost or not readily available, or may be associated with toxicity.
In the past few years, several substances with different properties have been studied in ex vivo and in vivo studies. Among these, only a few have been evaluated in clinical trials. At the present time, no definitive proof of the superiority of any solution has been provided and there is no systematic review or meta-analysis on this topic.
Objectives
!
The primary objective of this review was to identify and evaluate the safety and effectiveness of the available solutions for submucosal injection in endoscopic mucosal resection techniques (polypectomy, mucosal resection, and submucosal dissection) in human patients. As secondary objectives, we aimed to evaluate the duration of the effect, and the local deleterious effects of the solutions on the submucosal tissue, including those studies performed on animals.
Material and methods
!
We performed a systematic review and a meta-analysis to evaluate the effectiveness and safety of existing solutions for submucosal injection in endoscopic mucosal resection or dissection. This review was registered on the International prospective register of systematic reviews, PROSPERO: CRD42014009577. We considered all published randomized controlled trials for the quantitative synthesis. We performed a separate analysis for ESD and EMR. For the overall qualitative synthesis, we included nonrandomized trials, and observational studies (cohort, case-control, case series and case reports) evaluating the safety and effectiveness of submucosal injection solutions, regardless of blinding and language.
For the primary outcome, we included studies with humans submitted to upper or lower gastrointestinal endoscopy. For the secondary outcomes, we also included animal studies (including ex vivo). We included procedures where polypectomy, EMR or ESD were performed after the injection of submucosal solutions had taken place, either in the esophagus, stomach, colon or rectum.
Primary outcome
Complete resection of the lesion -histological determination of en bloc lesion free margins or endoscopic determination of no residual lesion. Endoscopic determination included the lack of residual lesion as reported by the endoscopist (with or without chromoendoscopy) or the inclusion of resection marks in the resected specimen or negative follow-up with tissue forceps biopsies from the resection site.
Secondary outcomes
Number of injections given; volume injected; duration of submucosal cushion; procedure time; endoscopic complications; residual lesion at follow-up; tissue injury.
Search strategy
We individually searched MEDLINE and included all studies published until March 2014. The electronic search was performed using the following key words: submucosal injection AND (endoscopic AND resection OR EMR OR ER OR mucosectomy OR endoscopic submucosal dissection OR ESD OR polypectom*) AND (solution* OR saline OR hyaluron* OR glycerol OR hypertonic OR fibrinogen OR epinephrine OR adrenaline OR dextrose OR blood OR gelatin OR jelly OR mannitol OR sodium alginate OR carboxymethylcellulose OR albumin OR succiny* OR indigo OR methylene) AND (complete resection OR R0 OR adverse event* OR complication* OR injection* OR volume OR duration).
Study selection
Two authors (AF, JM) independently scanned all titles and abstracts for relevance by electronic search. A third author (JT) intervened in case of disagreement.
Data extraction
Data extraction was performed independently by two authors (AF, JM) using a data extraction form to evaluate risk of bias according to the Cochrane Handbook for Systematic Reviews of Interventions. Studies were classified as high risk, low risk or unclear risk of bias. The end points were rate of complete resection (primary end point), number of submucosal injections, total volume (mL) used, duration of submucosal cushion (min), procedural time (min), rate of en bloc resection, incidence of endoscopic complications (perforation and bleeding), recurrence rate at follow-up and incidence of tissue injury or fibrosis.
Data synthesis
We provide a description of the findings including a summary of the study's results by intervention. We performed the analysis in STATA 13 (Stata Corp., Texas, United States) and the flow diagram using Review Manager 5. We meta-analyzed the complete resection rate and the incidence of adverse events (bleeding and perforation), using both randomeffects and fixed-effect meta-analyses but we only report the random-effects meta-analyses, since the two methods concur- Original article E2 THIEME This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
red. We present odds ratios with a 95 % confidence interval. Heterogeneity was assessed using the I 2 statistic. We produced a summary of findings table, rating the quality of evidence of the primary outcome.
Results
!
The electronic search resulted in a total of 159 published manuscripts that were scanned based on the title and abstract; 105 did not meet the inclusion criteria. The remaining 54 were assessed for eligibility using the full text articles and 11 were initially included for quantitative analysis. The flow diagram is shown in • " Fig. 1 , and the details of the studies are shown in• " Table 1 . Since there were only two studies on ESD and with different solutions (Mesna and SH) [17, 18] , a meta-analysis was not performed. In these studies, 53 lesions were randomized to Mesna (vs NS) and 33 to SH (vs NS). There were 88 lesions randomized as controls. In the Mesna RCT [17] , Sumiyama and colleagues aimed to evaluate the procedural time with Mesna compared to NS for gastric epithelial lesions. There was no statistically significant difference in this outcome. There were no differences in other outcomes such as R0 resection rate and adverse events (bleeding and perforation). Kim et al. [18] designed an RCT to compare SH to NS with "clinical usefulness" (a combination of en bloc resection and the need for additional injection) as the primary outcome. They randomized 76 gastric lesions and demonstrated a significant effect of SH in increasing the usefulness rate (90.9 % vs 61.1 %; P = 0.004). The nine EMR studies were all two-arm RCTs; eight of them used NS as the control group and only one used SH as the control [19] . Three trials evaluated SH solutions [20 -22] , three trials evaluated D50 [19, 23, 24] , and the others evaluated fibrinogen [25] , hydroxyethyl starch (HES) [26] , and succinylated gelatin (SG) [27] . The three studies that were excluded from the meta-analysis did not report the outcome of interest [28 -30] . Quality assessment of the nine RCT determined that six had a low risk of bias on the generation of the randomization sequence and allocation concealment; six had kept double blinding, while two studies failed to report adequate blinding of the subjects and personnel, and one reported no blinding. In the EMR studies, a total of 792 subjects and 793 lesions were included for analysis. The majority were male patients (56.7 %) and their mean age was 63.6 ± 3.9 years. Mean lesion size was 20.9 mm (range 8.5 -46 mm). After pooling, 209 lesions were randomized to SH (vs NS), 72 to D50 (vs NS), 82 to D50 (vs SH), 43 to SG, 25 to HES and 36 to fibrinogen. In total, 385 were randomized to NS as controls. Six studies were performed on colorectal lesions, one on gastric, and two using both gastric and colorectal lesions.
Meta-analysis results
Complete resection rate
All the nine studies included in the meta-analysis reported the resection efficacy and explicitly provided the complete resection rate (either by endoscopic evaluation or histological confirmation). The analysis results are shown as a forest plot in • " Fig. 2 Original article E3 THIEME with the studies having a low heterogeneity. The results indicate that the solution used does not have a significant impact on the resection efficacy. However, most solutions were only tried in one RCT which may limit the sensitivity to detect small effects. SH is the best studied solution and was compared to NS in three RCTs (423 patients) and the pooled results fail to suggest a difference between SH and NS with OR (95 %CI) 1.09 (0.82, 1.45). The overall plot indicates that the pooled results of the interventions (SH, HES, SG, D50, and fibrinogen) were not superior to the comparator, which was always NS with the exception of Hurlstone's trial which compared D50 to SH with OR (95 %CI) 1.07 (0.88, 1.29).
Bleeding rate
All the studies reported the post-polypectomy bleeding rate. Even though the bleeding definition was different across studies, the heterogeneity of the results was low. Original article E4 THIEME This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
sults for SH suggest that there is no beneficial effect on the bleeding risk when using this agent.
Post-polypectomy coagulation syndrome/perforation rate
Only four studies reported the occurrence of perforations or coagulation syndrome. The results are shown in • " Fig. 4 . There is only one RCT for each solution and none for SH. These studies were underpowered to detect significant differences in this specific outcome but the pooled analyses seem to suggest that NS may be effective in preventing perforations and coagulation syndrome (• " 
Other secondary end points
Due to the lack of data and heterogeneity of definitions, it was not possible to analyze the other proposed end points, such as number of submucosal injections, total volume (mL) used, duration of submucosal cushion (min), procedural time (min), rate of en bloc resection, recurrence rate at follow-up, and incidence of tissue injury or fibrosis.
Descriptive analysis
This section will evaluate the 54 studies included in the systematic review in order to assess the proposed outcomes. A summary of these studies is available in the Appendix. Sodium hyaluronate (SH) solution is widely used as an endoscopic submucosal injection material. It was first reported in animal models that the submucosal fluid cushion created by SH persists for longer periods of time than other available submucosal solutions [31 -34] . Its efficacy in EMR and ESD was also reported in clinical practice. Using 0.4 % SH as a submucosal injection solution in endoscopic resection enabled an effective lifting of a colorectal intramucosal lesion, reducing the need for additional injec- Original article E5 THIEME tions [22] . Fujishiro et al. [35] reported that a mixture of a high concentration of SH and glycerine had good results in ESD. SH was compared with NS in two randomized controlled trials that included patients with colorectal lesion < 20 mm managed with EMR. Yoshida et al. [20] concluded that EMR using 0.13 % SH applied to colon lesions of less than 20 mm diameter is more effective than NS for complete resection and maintenance of mucosal elevation, since complete resection was achieved in 74 of 93 lesions (79.5 %) in the SH group and 63 of 96 lesions (65.6 %) in the NS group (P < 0.05) and high mucosal elevation was maintained in 83.9 % of procedures in the SH group and 54.1 % in the NS group (P < 0.01). Kishihara et al. [21] also reported the superiority of NS solution for the ease of submucosal injection and snaring with less variability (P < 0.05). Finally, SH was compared to NS in a randomized controlled trial with gastric lesions proposed for ESD and it was shown that the usefulness rate and the volume of solution injected were significantly better in the 0.4 % SH group [18] . However, SH still faces some problems, namely its higher cost, requirement of an air-sealed container for storage, and the conflicting data concerning stimulation of tumor growth [36, 37] . Sodium alginate is an inexpensive high viscosity solution. Eun et al. demonstrated that mucosa-elevating capacity was comparable between 1 % sodium alginate solution and 0.5 % SH solution [38] . It also showed greater elevation when compared to that created by NS solution [39] . In a clinical study, 0.4 % SH solution exhibited no significant difference in catheter injectability but significant superiority in mucosa-elevating capacity over 0.6 % sodium alginate solution, with no findings indicative of tissue injury. En bloc resection was achieved in all cases, no adverse events were observed, and no case showed recurrence [40] . Further investigation is needed on the usefulness of this material as a submucosal injection solution for endoscopic procedures. With regard to dextrose solution, in a prospective, uncontrolled clinical study, Katsinelos et al. [41] first investigated the effectiveness of EMR using a hypertonic dextrose plus epinephrine solution as a submucosal cushion agent for the resection of 59 large sessile colorectal polyps, showing that 23/59 (39 %) were resected en bloc and 36/59 (61 %) in a piecemeal fashion. Also, Varadarajulu et al. [24] compared D50 and NS for injection assisted resection of 52 sessile gastrointestinal lesions. Compared with NS, lower volumes (median 2 vs 1 mL; P = 0.03) were required. Even after completion of resection, submucosal elevation persisted in 36 % of the patients randomly assigned to D50 compared with 20 % of those randomized to NS (P < 0.001). There were no significant differences in the rates of complete resection. Later, Katsinelos et al. [23] performed a prospective, double-blind, randomized study that compared EMR of 92 sessile rectosigmoid lesions ( > 10 mm) using D50 plus epinephrine or NS plus epinephrine. Injected solution volumes and number of injections were lower in the D50 group (P = 0.033 and P = 0.028, respectively). Submucosal elevation had a longer duration in the D50 group (P = 0.043). This difference mainly included large (≥ 20 mm) and giant (> 40 mm) lesions. There were 6 cases versus 1 case of post-polypectomy syndrome in the D50 and NS groups (P = 0.01). Dextrose solution was also compared with SH [19] in a RCT including 174 patients. R0 resection was achieved in 59 of the 82 lesions (72 %) in the dextrose group and in 56 of the 81 lesions (69 %) in the SH group (P > 0.1). Nevertheless, Fujishiro et al. [33] showed that injection of 20 % submucosal dextrose in an animal model was associated with mucosal and muscle damage on the day of injection, with ulceration extending to the submucosal layer within a week after injection.
Glycerol [34] , and later in EMR of colorectal laterally spreading tumors (LSTs) [42] . In this clinical study, particularly for nongranular, laterally spreading tumors (LST-NGs) < 20 mm, the glycerol group had a higher en bloc resection rate than the NS group (P < 0.01), however a similar recurrence rate and complications were achieved and there was no difference between en bloc resection for LST ≥ 20 mm. Sodium carboxymethylcellulose is a water-soluble polymer derived from cellulose. In vitro, the submucosal injection of sodium carboxymethylcellulose solution was able to dissect by itself most of the mucosal layer from the muscular layer at a concentration above 2.0 %. In vivo, three specimens were resected with 2.5 % sodium carboxymethylcellulose without difficulty. There were no procedure-related complications and histologic examination revealed no tissue damage [43] . Hydroxypropyl methylcellulose is a high viscosity agent that has been considered to be a good and low cost option readily available in the United States. Its superiority over NS solution in height and duration of mucosal elevation has been shown in animal studies [31, 32] . Further studies are needed to clarify the real benefits of this synthetic agent. Photocrosslinkable chitosan in DMEM/F12 medium is a viscous solution that crosslinks UV irradiation, resulting in an insoluble hydrogel. Photocrosslinkable chitosan hydrogel injection led to a longer lasting elevation with clearer margins compared with NS or SH solutions [44] , and was useful when used in ESD [44] . Furthermore, photocrosslinkable chitosan hydrogel may contribute to the healing of artificial ulcers after EMR and ESD [45] , which makes it a promising agent for endoscopic procedures and it should be evaluated in clinical trials after biocompatibility has been established. Succinylated gelatin (SG) is a widely available, inexpensive, safe, colloidal solution that exerts an oncotic pressure comparable with that of human albumin, with a favorable safety profile. In an animal study [46] , the mean EMR specimen dimension and surface area were significantly larger and the duration of mucosal elevation was significantly longer for SG (P = 0.005). Three perforations were recorded, two with SG and one with NS (P = 1.0). However, these perforations occurred in the proximal porcine colon which is thinner than distal porcine colon and human colon. The clinical efficacy of SG was evaluated by Moss et al. in a randomized double-blind trial, conducted to compare the performance of EMR with SG or NS for sessile lesions of the colon sized ≥ 20 mm [27] . The "Sydney Resection Quotient" (defined as lesion size in millimeters divided by the number of pieces to resect) was significantly different between groups, favoring SG; fewer injections per lesion (P = 0.002), lower injection volume (P = 0.009), and shorter procedure duration (P = 0.006) were reported with the SG group. There was also a non-significant trend towards higher en bloc resection rate with SG (30 % vs 15 %, P = 0.137). There were no perforations. Mesna (sodium-2-mercaptoethanesulfonate [C 2 H 5 NaO 3 S 2 ]) is a mucolytic agent that acts by cleaving disulfide bonds in proteins, thereby breaking down the connective tissue between anatomical planes. A preliminary clinical study that used submucosal mesna injection for ESD demonstrated the feasibility and safety of the procedure [47] . In an animal study comparing it with NS, there were no differences between groups related to ESD procedure time and en bloc resection, but mesna injection was asso- Original article E6 THIEME This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
ciated with a non-significant lower incidence of intraprocedural bleeding (P = 0.09) [48] . Recently, mesna solution was compared to NS in a randomized controlled trial and it showed that ESD time was not significantly different between groups, but multivariate analysis indicated that mesna reduced procedural challenges associated with submucosal dissection [17] . Autologous blood is readily available at low cost. Previous human and animal studies have demonstrated that autologous whole blood produced the longest durable cushion compared with standard agents [49] . The feasibility of EMR with blood submucosal injection was also reported with no complications [29, 50] . Regarding tissue injury, a study has shown that blood produces less tissue injury (measured as hydrops and tears) than NS [29] . However, some potential problems need to be clarified, namely the fact that autologous blood could hamper the specialist's view during the procedure and the possibility for blood coagulation [51] . Other agents such as fibrinogen mixtures, poloxamers, and photocrosslinkable chitosan have been reported for EMR with great enthusiasm. Compared with SH, fibrinogen mixtures and poloxamer solutions are significantly less expensive but remain substantially more expensive than NS [25] . A study that included EMR of 35 early gastric neoplasms showed that, after an initial injection of fibrinogen mixture, additional submucosal injection was not required for any lesion. The rates of en bloc resection and complete resection were, respectively, 82.9 % and 88.6 %. The en bloc resection rate was significantly lower for lesions over 20 mm in diameter (60 % vs. 92 %; P < 0.05) and for lesions on the lesser curvature or posterior wall of the stomach compared with those on the greater curvature or anterior wall (55.6 % vs. 92.3 %; P < 0.05). During follow-up, recurrence was noted in only one patient in whom the lesion had been resected piecemeal [52] . Later, the clinical efficacy of the fibrinogen mixture was evaluated in a RCT, comparing it with NS in EMR of early gastric neoplasms [25] . This study did not show differences between the two groups in the rates of en bloc resection and recurrence rate, but mean procedure time was significantly shorter in the fibrinogen group and additional submucosal injection to maintain elevation of the lesion was less frequently required in the fibrinogen group (P < 0.05). In addition, the use of fibrinogen mixtures for endoscopic resections still needs to be critically considered with regard to their potential to transfer infections. The poloxamer solution PS137 -25 was studied in porcine models, comparing it with NS and hydroxypropyl methylcellulose [53] , showing greater height of the initial mucosal elevation and longer mucosal elevation. Five EMRs were successfully performed after one injection of PS137 -25, with no thermal injury or perforations. Recently, other alternatives have been presented. A novel injectable drug eluting elastomeric biodegradable polymer (iDEEP) was developed to overcome the limitations of previous solutions, using both viscosity and gel formation through redox initiated crosslinking [54] , and showing more durable cushions than those formed with NS and SH. Carbon dioxide (CO 2 ) was also tested as an injection agent. Uraoka et al. [55] performed an animal study that showed the safety and efficacy of CO 2 as a satisfactory submucosal injection agent during ESD, the submucosal elevation created by CO 2 being longer than with either NS or sodium hyaluronic acid (P < 0.001). Creating and maintaining a CO 2 submucosal cushion of sufficient elevation was achieved combined with partial physical dissection of the submucosal layer, followed by complete endoscopic dissection of the CO 2 submucosal layer with ESD, resulting in successful en bloc resection with no complications. Cook Medical's (Bloomington, IN, United States) submucosal lifting gel consists of a proprietary combination of known biocompatible components that appears to be a promising safe and effective substance for submucosal injection. In an animal study, every injection resulted in adequate mucosal lifting, with no evidence of perforation, bleeding, gel extravasation through the serosal surface, or damage to surrounding tissue or organs [56] .
Discussion ! EMR and ESD are minimally invasive endoscopic procedures now accepted worldwide as a treatment modality in the removal of dysplastic and early malignant lesions limited to the superficial layers of the gastrointestinal tract [6, 7] . Endoscopic resection techniques are aided by mucosal elevation through the injection of a solution into the submucosal space in order to reduce complications. In this study, we tried to identify the best solution to use to lift the mucosal lesion. Our primary outcome was to evaluate complete resection of the lesion. All studies included in the meta-analysis [19 -27] provided the complete resection rate. SH is the best studied solution, being compared with NS in three RCTs [20 -22] . The remaining solutions, namely fibrinogen mixture [25] , hydroxyethyl starch [26] , and succinylated gelatin [27] , were only studied in one RCT each. Our study shows that the available evidence does not allow a robust conclusion to be drawn on the solution's effect on resection rate (OR 1.07; 95 %CI 0.88, 1.29) and, particularly, there is no difference between SH and NS (OR 1.09; 95 %CI 0.82, 1.45) (• " Fig.3 ). Regarding the complications, bleeding rate was reported in all studies, but the definition of bleeding was different across studies. We found that no single solution was shown to be more effective in decreasing the post-polypectomy bleeding rate, but HES, SG, and fibrinogen have shown a non-significant favorable trend against NS. The post-polypectomy coagulation syndrome/perforation rate was evaluated in four studies [19, 23, 26, 27] . From the analysis, we infer that NS may have a beneficial effect in preventing perforations and coagulation syndrome (• " Fig.5 ) with an OR (95 %CI) 0.27 (0.06, 1.19), especially when compared to HES (OR 0.15; 95 %CI 0.007, 3.03) and D50 (OR 0.16; 95 %CI 0.02, 1.38). However, these are rare events and a much larger sample size would be needed to determine a more precise effect estimate. In the descriptive analysis section, we analyzed several solutions with different properties. Many solutions have been tested in animal studies and most seem more effective for mucosal elevation than NS, without significant differences in complication rates. We highlight that the superiority of these solutions must be evaluated in RCTs. According to our results, no solution was proven to be superior in complete resection rate, post-polypectomy bleeding, or coagulation syndrome/perforation incidence. We emphasize the need for continuing research in this topic. Original article E7 THIEME per protocol analysis. Also two of the RCTs were not adequately blinded. The studies include lesions in the stomach, in the colon or rectum, and the effect of the submucosal injection may be different according to the anatomical site. In addition, the size of the lesions was quite different between studies, ranging from 8.5 mm to 46 mm lesions (EMR studies) and this represents a heterogeneous sample to pool. We chose to consider complete resection as either endoscopic or histologically assessed in the original studies even though they may not be perfectly correlated. In the adverse event reporting, there were also a wide range of definitions for post-polypectomy bleeding and some of the studies reported immediate and/or delayed bleeding rates, while we counted the totals.
Potential biases and limitations
Conclusions
!
In summary, there are many solutions being commonly used for submucosal injection and many more under research. There is a lack of high quality evidence. According to the present meta-analysis, it is not possible to select one solution over the others by considering complete resection rates and procedural safety. There was a trend towards a higher risk of bleeding and a lower risk of perforation/post-polypectomy syndrome with NS. More trials may be needed to select the best solution. At the moment, RCTs should use NS as the control group. The median duration of mucosal elevation was longer with HPMC/dextran, HES and SH compared with NS (P < 0.05). There were no significant differences between SH and HPMC/dextran and HES (P > 0.05). 11, 9, 7 and 6 11, 10, 8 and 7 11, 10, 9 and 9 13, 12, 11.6 and 11.3
The initial mucosal elevations of all SH concentrations were higher than NS (P < 0.05) and all concentrations of SH maintained a greater degree of mucosal elevation than NS (P < 0.05). 11.5, 10, 9.5 and 9
12, 11, 9 and 9
The initial mucosal elevation of 0.13 %, 0.2 %, and 0.4 % SH were higher than NS (P < 0.05) and 0.13 %, 0.2 %, and 0.4 % SH maintained a greater degree of mucosal elevation than NS (P < 0.05). There was no significant difference in the height of mucosal elevation between SA and SH and both maintain a higher mucosal elevation between 5 and 30 minutes when compared to other solutions (P < 0.05).
Animal study (invivo)
Histologic findings of the submucosal cushion, effect of injection on the tissue and effect on healing process of EMRinduced ulcers 
% SA
A clear separation of the mucosal layer from the proper muscle layer was achieved by injecting SA solution. Histological examination of EMR-induced artificial ulcers revealed no apparent tissue damage and showed normal healing
NS
The elevation created by the 2 %, 3 % and 4 % SA solutions and the SH solution was significantly greater and maintained a greater degree of elevation than NS (P < 0.05). Whole blood is more effective in generating longlasting mucosa elevation than any other commonly used solution (P < 0.05).
Mean mucosa elevation before and up to 60 minutes after injection A significantly longer duration was obtained after injection of hydroxyethyl starch, 0.25 % and 0.5 % hyaluronic acid, serum, and plasma. However, whole blood generated a longer-lasting mucosa elevation than all other agents. 
Cook Medical Gel
The gel appears to be a safe injectate that provides a submucosal cushion with a duration that is longer than other available injectates for EMR and ESD.
Evaluation of submucosal cushion Every injection resulted in adequate mucosal lifting with a shoulder and defined margin and no cases of gel extravasation.
The submucosal cushion was still present at the time of organ extraction without evidence of perforation, bleeding or tissue damage.
Complications
Necropsy demonstrated no evidence of perforation, bleeding or gel extravasation. Degree of hydrops The hydrops in the NS group were more extensive than those in the plasma solution injected group (P = 0.011)
The in vivo animal and human study demonstrated that whole blood or plasma solution may outperform normal saline due to its unique lifting ability, less tissue damage and marked effective submucosal blunt dissection.
Degree of tears Tearing in the NS group was less than that in the plasma injected group (P = 0.008) Degree of hydrops The degree of hydrops in the NS group was more extensive than that in the group with whole blood (P < 0.001).
Degree of tears
The effective submucosal tearing in the group with NS was less than that in the group with blood (P < 0.001).
Abbreviations: min -minutes; NS -normal saline; SH -sodium hyaluronate; HA This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
